Description

Inbec Tablet (Abacavir/Dolutegravir/Lamivudine) – Prescription Antiretroviral Medicine for HIV-1 Treatment

Inbec Tablet is a prescription antiretroviral medicine formulated with Abacavir, Dolutegravir, and Lamivudine, a fixed-dose combination used as a complete treatment regimen for Human Immunodeficiency Virus Type 1 (HIV-1) infection in adults and eligible adolescents. This combination contains Dolutegravir, an Integrase Strand Transfer Inhibitor (INSTI), along with Abacavir and Lamivudine, two Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Together, these medicines work by blocking different stages of HIV replication, helping reduce the amount of virus in the body and supporting immune system function.

Inbec Tablet helps maintain viral suppression, supports immune recovery, and reduces the risk of HIV-related complications when taken consistently as prescribed. The medicine does not cure HIV infection and should only be used under the supervision of a qualified healthcare professional.

The medicine is prescribed only after proper medical evaluation. Before starting treatment, patients should generally be screened for the HLA-B*5701 genetic marker because individuals who test positive have a significantly increased risk of serious hypersensitivity reactions to Abacavir.

• Key Features

1. Contains Abacavir, Dolutegravir, and Lamivudine
2. Prescription-only antiretroviral medication
3. Complete once-daily oral HIV treatment regimen
4. Combines one INSTI with two NRTIs
5. Helps suppress HIV-1 viral replication
6. Supports long-term HIV management
7. Manufactured under quality pharmaceutical standards

How to Take Inbec Tablet

For the best therapeutic effect, take Inbec Tablet exactly as directed by your healthcare provider. It is generally taken once daily, with or without food. Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your physician.

Take the medicine at the same time each day to maintain consistent drug levels. Do not skip doses or discontinue treatment without medical advice, as doing so may increase the risk of viral resistance and treatment failure.

If taking calcium supplements, iron supplements, antacids, or multivitamins containing minerals, follow your healthcare provider’s instructions regarding timing, as these products may reduce Dolutegravir absorption.

• General Dosage Reference

Medical Condition	Recommended Adult Dose
HIV-1 Infection	One tablet once daily
Long-Term HIV Management	Continue treatment as prescribed by the healthcare provider
Renal or Hepatic Impairment	Treatment suitability determined by the treating physician

The exact dosage should always be determined by your healthcare provider based on treatment history, kidney and liver function, genetic testing (HLA-B*5701), and current HIV treatment guidelines.

Safety Information

Before starting Inbec Tablet, tell your healthcare provider if you have liver disease, kidney disease, hepatitis B or hepatitis C infection, heart disease, or any known allergy to Abacavir, Dolutegravir, Lamivudine, or any ingredients in the medicine.

Patients should undergo HLA-B*5701 testing before initiating Abacavir-containing therapy, as those who test positive should not use Abacavir due to the risk of potentially life-threatening hypersensitivity reactions.

Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using this medicine. Inform your physician about all prescription medicines, over-the-counter drugs, vitamins, herbal supplements, and antacids, as some medicines may interact with this combination.

Most people tolerate Inbec Tablet well when taken as prescribed. However, some individuals may experience headache, nausea, diarrhea, fatigue, insomnia, or dizziness. Serious side effects may include Abacavir hypersensitivity reactions, severe allergic reactions, liver toxicity, lactic acidosis, severe skin reactions, and mood changes. Seek immediate medical attention if you develop fever, rash, breathing difficulty, severe abdominal pain, yellowing of the skin or eyes, or swelling of the face or throat.

Regular monitoring of liver function and HIV treatment response is recommended throughout therapy.

Product Specifications

Specification	Information
Brand	Inbec Tablet
Generic Name	Abacavir / Dolutegravir / Lamivudine
Active Ingredients	Abacavir + Dolutegravir + Lamivudine
Strength	As Prescribed
Dosage Form	Oral Tablet
Drug Class	Antiretroviral (INSTI + NRTI Combination)
Route of Administration	Oral
Prescription Status	Prescription Required
Storage	Store below 30°C in a cool, dry place away from moisture and direct sunlight

Frequently Asked Questions

Can Inbec Tablet be taken with food?

Yes. Inbec Tablet may generally be taken with or without food unless your healthcare provider advises otherwise.

Is Inbec Tablet a cure for HIV?

No. Inbec Tablet does not cure HIV infection. It helps suppress viral replication and maintain viral control when taken consistently as prescribed.

Why is HLA-B*5701 testing recommended before taking Inbec Tablet?

Patients should be screened for the HLA-B*5701 genetic marker because those who test positive have a significantly increased risk of developing a serious hypersensitivity reaction to Abacavir.

Can Inbec Tablet be used alone?

Yes. Inbec Tablet is a complete fixed-dose combination regimen intended for HIV treatment when prescribed by a qualified healthcare professional.

What should I do if I miss a dose?

Take the missed dose as soon as you remember unless it is almost time for your next scheduled dose. Do not take two doses together. Consult your healthcare provider if you are unsure.